Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  CardiovascularBG ControlIssue 730

High-normal A1c Signals CAD Risk in Nondiabetic Patients

Among patients who don't have diabetes, high-normal HbA1c levels (at or above 5.8%) are strongly correlated with the risk of coronary artery disease.... 

Advertisement

In what they described as the first large-scale study to assess the relationships among HbA1c, CAD, and carotid intima-medial thickness, researchers enrolled 1,703 consecutive patients undergoing either elective or urgent coronary angiography at a single medical center during a 5-year period. These nondiabetic patients were divided into tertiles according to their HbA1c levels: low (less than 5.5%), intermediate (5.5%-5.79%), or high (5.8% or higher), reported Dr. Monica Verdoia of the cardiology department, Maggiore della Carita Hospital, Novara (Italy), and her associates.

HbA1c was significantly associated in a dose-dependent fashion with the prevalence of CAD on angiography (odds ratio, 1.33). CAD prevalence was 66.9% in patients who had low-normal HbA1c, 73.7% in those with intermediate HbA1c, and 78.6% in those with high-normal HbA1c. This association remained robust after the data were adjusted to account for many confounding factors, including patient age and sex; the presence or absence of hypertension, hypercholesterolemia, renal failure, and previous myocardial infarction; and the use or nonuse of medications including angiotensin receptor blockers, beta-blockers, nitrates, statins, or diuretics, the investigators said.

This strong association between high-normal HbA1c and CAD prevalence persisted across every high-risk subgroup that was assessed. HbA1c also was independently and strongly associated with carotid intima-medial thickness and the prevalence of carotid plaques on ultrasonography.

The best cutoff value for predicting the presence of significant CAD was determined to be 5.8%. Even though this level is within the normal range, it "should be regarded as a risk factor for atherosclerosis," Dr. Verdoia and her associates said.

Further research is needed to confirm these findings and to assess whether more aggressive preventive strategies, such as lifestyle changes, the use of statins, or antiplatelet therapies, might reduce the development and progression of atherosclerosis in such patients, they added.

Practice Pearls:
  • The prevalence of CAD was 66.9% in nondiabetic patients who had low-normal HbA1c, 73.7% in those with intermediate HbA1c, and 78.6% in those with high-normal HbA1c.
  • A1c levels (at or above 5.8%) are strongly correlated with the risk of coronary artery disease

Am. J. Prev. Med. 2014 April 21 [doi: 10.1016/j.amepre.2014.02.002]).  

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 May, 2014 and appeared in  CardiovascularBG ControlIssue 730

Past five issues: SGLT-2 Inhibitors Special Edition July 2015 | Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
Posted July 17, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
Can the Insulin Patch Become a Reality?
Posted July 03, 2015
Ancestral Diets Can Determine Vulnerability to Type 2 Diabetes
Posted July 17, 2015
New Evidence Suggests Pioglitazone Reduces Dementia Risk 42%
Posted July 03, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you have any patients on a dual therapy of a DPP-4 and a SGLT-2 who have reached their goal A1c?

CME/CE of the Week
Marie Williams, DPM

Category: Wound Care
Credits: .75